PCT Patents in Blood Anticlot Technology, Medications and
Medical Devices Published in 2012
Clck to enlarge and view details

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

WIPO - WORLD PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2012



Publication No.: WO8092584B2  Published: 10/Jan/2012

Title: GLUE FROM SLAUGHTERHOUSE ANIMAL BLOOD

Applicant/Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION

Application No.: 12/358926   Filing Date: 23/Jan/2009

Abstract:

Disclosed is a process for making an animal blood adhesive and the resulting adhesive composition. The adhesive is made by adding to fresh, whole animal blood, without dewatering the blood, an anticoagulant and a preservative. Lime is then added to the anticoagulated, preserved blood, and the pH is adjusted to between about 9 and about 11. A curing agent (such as potassium silicate, sodium silicate and aluminum dihydrogen phosphate) and ammonia are then added to the mixture to yield the animal blood adhesive. The adhesive can be made from any animal blood, such as bovine, porcine, or avian blood. The resulting adhesive is useful for adhering wood-based products, such as plywood and particle board.

Priority: US2008-022948P Applic. Date: 2008-01-23

Inventor: GUNASEKARAN SUNDARAM [US]; LIN HAILIN [US]


Publication No.: WO8092837B2  Published: 10/Jan/2012

Title: Fibrin based glue with functionalized hydrophilic polymer protein binding agent

Applicant/Assignee: BIOMET MANUFACTURING CORP

Application No.: 11/741333   Filing Date: 27/Apr/2007

Abstract:

The present invention provides a non-liquid biomaterial that may be used as a surgical sealant, a suture support, a blood flow controller, an adhesion reducing agent, an adhesion preventing agent, a tissue support, a tissue filler, a wound dressing or a combination thereof. The non-liquid biomaterial may comprise a blood derived material such as plasma, platelet poor plasma, platelet rich plasma or a material derived from blood containing tissue aspirate, such as bone marrow aspirate, a protein binding agent and a polymerizing agent. Methods for making and using the non-liquid biomaterial are also provided.

Priority:

Inventor: ENYART HILLARY [US]; HOEPPNER JACY [US]; LEACH MIKE [US]; STEGER SHON [US]; SUNDARAMURTHY SONA [US]


Publication No.: WO8101344B2  Published: 24/Jan/2012

Title: Device and method for high-throughput quantification of MRNA from whole blood

Applicant/Assignee: HITACHI CHEMICAL RESEARCH CENTER, INC, HITACHI CHEMICAL CO., LTD

Application No.: 11/376018   Filing Date: 15/Mar/2006

Abstract:

Disclosed are a method, device kit, and automated system for simple, reproducible, and high-throughput quantification of mRNA from whole blood. More particularly, the method, device, kit and automated system involve combinations of leukocyte filters attached to oligo(dT)-immobilized multi-well plates.

Priority: US2003-698967 Applic. Date: 2003-10-30; US2004-796298 Applic. Date: 2004-03-09; WO2003US12895 Applic. Date: 2003-04-24; US2002-375472P Applic. Date: 2002-04-24

Inventor: MITSUHASHI MASATO [US]


Publication No.: WO8101358B2  Published: 24/Jan/2012

Title: Method of profiling gene expression in a subject having disease

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757914   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8101366B2  Published: 24/Jan/2012

Title: Assessment of Patients with Sepsis to Determine a Requirement for Therapeutic Intervention with an Anti-Inflammatory and/or Anticoagulatory Agent

Applicant/Assignee: ANTIBODYSHOP A/S

Application No.: 12/517085   Filing Date: 19/Dec/2007

Abstract:

Methods of selecting patients with sepsis for treatment with an anti-inflammatory and/or anticoagulatory agent are provided.

Priority: US2006-876059P Applic. Date: 2006-12-20; WO2007DK50194 Applic. Date: 2007-12-19

Inventor: BANGERT KRISTIAN [DK]; UTTENTHAL LARS OTTO [ES]


Publication No.: WO8101379B2  Published: 24/Jan/2012

Title: PREPARATION OF LOW BLEEDING ANTICOAGULANT FUSION PROTEIN AND ITS USE

Applicant/Assignee: BEIJING SANLY SCI-TECH DEVELOP INC. LTD, INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA, INSTITUTE OF RADIATION MEDICINE ACADEMY OF MILITARY MEDICAL SCIENCE

Application No.: 12/519309   Filing Date: 11/Dec/2007

Abstract:

Provided is an anticoagulant fusion protein comprising oligopeptide recognizable and cleavable by either factor XIa and factor Xa or thrombin and factor Xa. Also provided are the preparation method of the anticoagulant fusion protein and medicinal use thereof.

Priority: CN20061165756 Applic. Date: 2006-12-15; WO2007CN03526 Applic. Date: 2007-12-11

Inventor: WU ZUZE [CN]; YU AIPING [CN]; ZHANG CHUANLING [CN]; TANG ZHONGXIONG [CN]


Publication No.: WO8105258B2  Published: 31/Jan/2012

Title: Citrate anticoagulation system for extracorporeal blood treatments

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 11/602827   Filing Date: 21/Nov/2006

Abstract:

A hemofiltration system and method for pumping blood from a patient's blood stream into an access line, introducing an anticoagulant solution into the pumped blood, filtering the pumped blood and delivering it to a return line, introducing a substitution fluid into the pumped blood, introducing a calcium and magnesium solution into the blood traveling through the return line, and returning the blood back to the patient's blood stream.

Priority: US2005-739086P Applic. Date: 2005-11-22; WO2000EP03583 Applic. Date: 2000-04-20; US2001-959543 Applic. Date: 2001-10-23; US2003-742137 Applic. Date: 2003-12-19; EP19990201302 Applic. Date: 1999-04-26

Inventor: LANNOY JEAN-MICHEL [FR]


Publication No.: WO8110358B2  Published: 07/Feb/2012

Title: Method of profiling gene expression in a subject having prostate cancer

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757931   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US1999-115125P Applic. Date: 1999-01-06; US2000-477148 Applic. Date: 2000-01-04; US2006-568730 Applic. Date: 2006-02-17; US2009-573856 Applic. Date: 2009-10-05

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8114465B2  Published: 14/Feb/2012

Title: PROCESS FOR PREPARING A SUBSTRATE COATED WITH A BIOMOLECULE

Applicant/Assignee: ENSION, INC

Application No.: 12/061212   Filing Date: 02/Apr/2008

Abstract:

Processes are provided for preparing a substrate coated with a biomolecule, comprising: a) providing a substrate

b) coating the substrate with a polysiloxane, typically by exposing the substrate to a reactive gas containing siloxane functional groups and to plasma energy to yield a plasma-deposited polysiloxane surface on the substrate

c) rendering the polysiloxane surface amino functional

and d) contacting the amino-functional polysiloxane surface with a biomolecule under conditions effective to attach the biomolecule to the substrate. The coated substrate may be a medical device that demonstrates an ability to maintain gas permeability when in contact with blood or blood components, compared to a substantially identical medical device that has not been coated with a biomolecule using this process.

Priority: US2007-909553P Applic. Date: 2007-04-02

Inventor: CAHALAN PATRICK [US]; CAHALAN LINDA [US]; JOHNSON GREG [US]; GARTNER MARK [US]


Publication No.: WO8114597B2  Published: 14/Feb/2012

Title: Method of profiling gene expression in a subject undergoing a treatment

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757921   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587384 Applic. Date: 2009-10-06; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8114842B1  Published: 14/Feb/2012

Title: Nanoparticles for drug delivery

Applicant/Assignee: GP MEDICAL, INC, NATIONAL TSING HUA UNIVERSITY

Application No.: 11/881185   Filing Date: 26/Jul/2007

Abstract:

The invention discloses the nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent for treating wet AMD. The nanoparticles are characterized with a positive surface charge and their enhanced permeability for paracellular drug delivery.

Priority: US2005-029082 Applic. Date: 2005-01-04; US2004-958864 Applic. Date: 2004-10-05; US2006-848756P Applic. Date: 2006-10-02; US2007-879761P Applic. Date: 2007-01-10; US2005-284734 Applic. Date: 2005-11-21

Inventor: SUNG HSING-WEN [TW]; TU HOSHENG [US]


Publication No.: WO8123789B2  Published: 28/Feb/2012

Title: Central nervous system cooling catheter

Applicant/Assignee:

Application No.: 11/418849   Filing Date: 05/May/2006

Abstract:

The invention provides a method and apparatus for performing selective hypothermia to the brain and spinal cord for injury protection without the need for systemic cooling. A flexible catheter is inserted into the cerebral lateral ventricle or spinal subdural space. The catheter has lumens with a heat transfer element. The lumens of the catheter circulate a coolant and communicate at the distal heat transfer element for transfer of heat from the cerebrospinal fluid. Furthermore a method of maintaining catheter patency and providing blood clot hemolysis and drainage is also provided through the use of ultrasonic and/or laser energy delivered through the catheter.

Priority: US2002-136003 Applic. Date: 2002-04-29

Inventor: KHANNA ROHIT [US]


Publication No.: WO8129103B2  Published: 06/Mar/2012

Title: Use of a platelet preservation composition comprising a short to ultra-short acting antiplatelet agent and anticoagulant with an oxygen carrier

Applicant/Assignee: BIOVEC, LLC, BIOVEC TRANSFUSION, LLC

Application No.: 12/109784   Filing Date: 25/Apr/2008

Abstract:

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US2006-330132 Applic. Date: 2006-01-12; US2005-643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]; MOUSA SHAKER [US]


Publication No.: WO8130369B2  Published: 06/Mar/2012

Title: MEASURING HEMATOCRIT AND ESTIMATING HEMOGLOBIN VALUES WITH A NON-INVASIVE, OPTICAL BLOOD MONITORING SYSTEM

Applicant/Assignee: HEMA METRICS, LLC, FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 12/265392   Filing Date: 05/Nov/2008

Abstract:

An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting.

The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Priority:

Inventor: BARRETT LOUIS LEEGRANDE [US]; PETERSON DAVID WAYNE [US]; SAMMANN KRISTIAN ALLEN [US]


Publication No.: WO8133194B2  Published: 13/Mar/2012

Title: System and Method for Delivery of Regional Citrate Anticoagulation to Extracorporeal Blood Circuits

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 11/829261   Filing Date: 27/Jul/2007

Abstract:

The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Priority: US2006-791055P Applic. Date: 2006-04-11; US2006-845646P Applic. Date: 2006-09-19; US2006-775728P Applic. Date: 2006-02-22; WO2007US62589 Applic. Date: 2007-02-22; US2006-790882P Applic. Date: 2006-04-11; US2006-775729P Applic. Date: 2006-02-22

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Publication No.: WO8133674B2  Published: 13/Mar/2012

Title: Method of profiling gene expression in a subject having diabetes

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757928   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587382 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8133675B2  Published: 13/Mar/2012

Title: Method of profiling gene expression in a subject having an infectious disease

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757934   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587385 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8137299B2  Published: 20/Mar/2012

Title: WEARABLE ULTRAFILTRATION DEVICE

Applicant/Assignee: NATIONAL QUALITY CARE, INC, FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 12/574128   Filing Date: 06/Oct/2009

Abstract:

An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Priority: US2001-085349 Applic. Date: 2001-11-16; US2002-251937 Applic. Date: 2002-09-19

Inventor: GURA VICTOR [US]; RAMBOD EDMOND [US]


Publication No.: WO8137696B2  Published: 20/Mar/2012

Title: BIOMIMETIC COMPOSITION REINFORCED BY A POLYELECTROLYTIC COMPLEX OF HYALURONIC ACID AND CHITOSAN

Applicant/Assignee: TISSUE ENGINEERING CONSULTANTS, INC

Application No.: 12/410537   Filing Date: 25/Mar/2009

Abstract:

The present invention relates to a three dimensional, malleable cell culture composition and method of forming the same comprising hyaluronic acid, chitosan and a polyelectrolytic complex of hyaluronic acid and chitosan. These three components in combination constitute an initial microenvironment for support of stromal cells, and their undifferentiated mesenchymal cell progeny. The tissue engineering device and method of forming the same comprising hyaluronic acid and chitosan and the use of said device with compositions of pluripotent cells and various formulations of cell culture media for repair of tissues is disclosed.

Priority: US2004-999848 Applic. Date: 2004-11-30; US2003-525965P Applic. Date: 2003-12-01

Inventor: BREKKE JOHN H [US]


Publication No.: WO8137699B2  Published: 20/Mar/2012

Title: Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use

Applicant/Assignee: TRUSTEES OF PRINCETON UNIVERSITY

Application No.: 10/472071   Filing Date: 23/Oct/2003

Abstract:

This invention discloses a process for making nanopanticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in an nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers.

Furthermore, the resulting particles exhibit sufficient stability for post processing as desired. The invention also discloses two apparatuses for the production of nanoparticles of amphiphilic copolymers by flash precipitation.

Priority: WO2002US10715 Applic. Date: 2002-03-29

Inventor: JOHNSON BRIAN K [US]; PRUD HOMME ROBERT K [US]


Publication No.: WO8148072B2  Published: 03/Apr/2012

Title: Method of profiling gene expression in a subject having heart failure

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757930   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06; US2009-573863 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8148326B2  Published: 03/Apr/2012

Title: Flowable carrier matrix and methods for delivering to a patient

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 12/635289   Filing Date: 10/Dec/2009

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenetic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL B [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Publication No.: WO8148609B2  Published: 03/Apr/2012

Title: Uses for Yerba Santa

Applicant/Assignee:

Application No.: 12/487942   Filing Date: 19/Jun/2009

Abstract:

Methods of in vitro propagation of plants of the genus Eriodictyon are described, including, in particular embodiments, plants of the species E. californicum, E. trichocalyx and E. sessilifolium. Methods of producing transgenic plants of the genus Eriodictyon are also described, along with methods of producing recombinant proteins in such plants. Compositions and methods for administering recombinant proteins produced in these plants are also described.

Priority: US2008-074376P Applic. Date: 2008-06-20

Inventor: KOPROWSKI HILARY [US]; POGREBNYAK NATALIA [US]; GOLOVKIN MAXIM [US]


Publication No.: WO8157774B1  Published: 17/Apr/2012

Title: Apparatus for stem cell collection and methods thereof

Applicant/Assignee: DEKA PRODUCTS LIMITED PARTNERSHIP

Application No.: 11/687149   Filing Date: 16/Mar/2007

Abstract:

Apparatus and methods for collecting stem cells from an umbilical cord utilize a plurality of needles that are inserted into the umbilical cord. The needles may be fenestrated, and may have a common output to a line via which the stem cells are collected. A negative pressure source, such as a vacuum, may be used to draw the cells through the needles and the line. Apparatus for holding the umbilical cord, compressing the umbilical cord, positioning the plurality of needles in relation to the umbilical cord, guiding insertion of the needles toward and into the umbilical cord, withdrawing blood from the umbilical cord, and/or collecting blood withdrawn from the umbilical cord may be provided. One or more one-way check valves may be used to control fluid flow. Additionally or alternatively, a shunt may be used during blood collection to prevent backflow through the needles.

Priority: US2006-782755P Applic. Date: 2006-03-16

Inventor: ALTOBELLI DAVID E [US]


Publication No.: WO8158062B2  Published: 17/Apr/2012

Title: Disposable Fluid Sample Collection Device

Applicant/Assignee:

Application No.: 10/578453   Filing Date: 05/Nov/2004

Abstract:

A fluid sampling device (100) that operates by a combination of capillary action to collect a small fluid sample, and by pressure differential when inserted into an analyzer (200) to expose the fluid sample for testing by the analyzer (200). The device is especially suited for use as a disposable blood sampling unit designed to interface with a blood analyzer, albeit the concept of the invention may be employed for sampling and testing virtually any fluids.

Priority: US2003-517573P Applic. Date: 2003-11-05; WO2004US36909 Applic. Date: 2004-11-05

Inventor: DYKES CHRIS [US]; LANE BEN [US]; ABBOTT MIKE [US]; MURPHY BRIAN [US]; DIXON EVA [US]; BEAN BRIAN [US]; LIPFORD BRIAN [US]; REED SAMUEL [US]


Publication No.: WO8167935B2  Published: 01/May/2012

Title: PERCUTANEOUS AORTIC VALVE

Applicant/Assignee: REX MEDICAL, L.P

Application No.: 12/880456   Filing Date: 13/Sep/2010

Abstract:

The present invention provides a valve configured for insertion on the proximal and distal sides of a heart valve annulus to replace the heart valve of a patient. The valve comprises a first substantially annular portion adapted to be positioned on a proximal side of the annulus of a patient and a second substantially annular portion adapted to be positioned on a distal side of the annulus of a patient, wherein at least one of the first and second substantially annular portions is movable towards the other portion to a clamped position to clamp around the annulus. The second portion has a flow restricting portion extending therefrom and is movable between a first position to permit the flow of blood and a second position to restrict the flow of blood.

In one embodiment, the valve has a suture joining the first and second portions to draw the first and second portions into closer proximity and a cinch member to secure the suture to maintain the first and second portions in the clamped position. In another embodiment, the first and second portions are connected by a first segment which biases the first and second portions toward the clamped position.

Priority: US2008-288620 Applic. Date: 2008-10-22; WO2001US43879 Applic. Date: 2001-11-14; US2000-252187P Applic. Date: 2000-11-21; US2003-429536 Applic. Date: 2003-05-05; US2005-222570 Applic. Date: 2005-09-09

Inventor: MCGUCKIN JR JAMES F [US]; HINCHLIFFE PETER W J [US]


Publication No.: WO8173595B2  Published: 08/May/2012

Title: Methods and Compositions for the Inhibition of Thrombus Formation

Applicant/Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Application No.: 11/579291   Filing Date: 27/Apr/2005

Abstract:

The present invention is directed to anti-platelet peptides that may be used in various methods for the treatment or prophylaxis of thrombosis. More specifically, the specification describes methods and compositions for making and using compositions GPIb[alpha] fragments as anti-platelet agents. The present invention is also directed to peptides that inhibit intracellular function of 14-3-3.

Priority: US2004-568042P Applic. Date: 2004-05-04; WO2005US14528 Applic. Date: 2005-04-27

Inventor: DAI KESHENG [US]; DU XIAOPING [US]


Publication No.: WO8177738B2  Published: 15/May/2012

Title: BONE VOID FILLING TUBE AND SHEAR MECHANISM

Applicant/Assignee: ARTHREX, INC

Application No.: 12/840931   Filing Date: 21/Jul/2010

Abstract:

Apparatus and methods for delivering a clotted biological component (such as blood, autologous conditioned plasma (ACP), platelet-rich plasma (PRP), bone marrow aspirate (BMA), demineralized bone matrix, anticoagulants and/or clotting agents, or combination of these materials) into a tissue void (for example, a bone void such as a bone tunnel, socket, opening or cavity), and then cutting the clotted biological component with a cutting or shearing mechanism at the tissue surface. The apparatus is provided with a tube and a cutting or shearing mechanism (provided on or within the distal end of the tube) that is actuated to cut or break off the clot at the desired insertion length. The tube may then be placed over the next tissue void so that the obturator drives the next clot into the next tissue void until all tissue voids are filled.

Upon insertion at the defect site, the biological component advances the healing of the damaged tissue and tissue growth.

Priority: US2009-229159P Applic. Date: 2009-07-28

Inventor: SCHMIEDING REINHOLD [US]; BENEDICT ROBERT [US]


Publication No.: WO8178525B2  Published: 15/May/2012

Title: FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Applicant/Assignee: LEGOCHEM BIOSCIENCE LTD

Application No.: 13/002271   Filing Date: 05/Jun/2009

Abstract:

Disclosed are novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions containing the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa.

Priority: WO2009KR03008 Applic. Date: 2009-06-05; KR20080064178 Applic. Date: 2008-07-03

Inventor: SONG HO YOUNG [KR]; CHO YOUNG LAG [KR]; LEE DAE YON [KR]; PARK HEE SOCK [KR]; BAEK SUNG YOON [KR]; CHAE SANG EUN [KR]; JO SANG HUI [KR]; KIM YEON OK [KR]; LEE HYANG SOOK [KR]; PARK JU HYUN [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; KIM YONG ZU [KR]


Publication No.: WO8187886B2  Published: 29/May/2012

Title: BLOOD CELL SORTING METHODS AND SYSTEMS

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION

Application No.: 12/987575   Filing Date: 10/Jan/2011

Abstract:

The invention relates to methods of isolating white blood cells (WBCs) from a sample, e.g., whole blood, using magnetic particles that specifically bind to WBCs and a series of specific steps and conditions. The methods can include one or more of decreasing the viscosity of the sample prior to WBC isolation, agitating the sample at specified frequencies, and/or using a sample container arranged such that all of the sample is placed in close proximity (e.g., within 5, 2, 1, or 0.5 mm) to the source of the magnetic field. The new methods provide for isolation of WBC preparations with high yield, purity, and viability. The methods are designed for compatibility with automation protocols for rapid processing of multiple samples.

Priority: US2006-646985 Applic. Date: 2006-12-28; US2005-754426P Applic. Date: 2005-12-28

Inventor: FAUSTMAN DENISE L [US]; BURGER DOUGLAS E [US]


Publication No.: WO8188045B2  Published: 29/May/2012

Title: Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

Applicant/Assignee: DYAX CORP., A MASSACHUSETTS CORPORATION, DYAX CORP

Application No.: 11/804388   Filing Date: 18/May/2007

Abstract:

Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.

Priority: US2005-125639 Applic. Date: 2005-05-09; US2004-953902 Applic. Date: 2004-09-27

Inventor: BLAIR HENRY [US]; BECK THOMAS [US]; LADNER ROBERT C [US]


Publication No.: WO8195403B2  Published: 05/Jun/2012

Title: Selective resonance of bodily agents

Applicant/Assignee: SEARETE LLC, A LIMITED LIABILITY CORPORATION OF THE STATE OF DELAWARE, THE INVENTION SCIENCE FUND I, LLC

Application No.: 11/441786   Filing Date: 26/May/2006

Abstract:

A chemical composition is introduced into the body and selectively or preferentially excited by the application of a score comprising a series of differing energy inputs that selectively resonate chemical structures of the composition.

Priority: US2005-186633 Applic. Date: 2005-07-21

Inventor: ISHIKAWA MURIEL Y [US]; JUNG EDWARD K Y [US]; LEUTHARDT ERIC C [US]; MYHRVOLD NATHAN P [US]; WOOD JR LOWELL L [US]


Publication No.: WO8198238B2  Published: 12/Jun/2012

Title: Flowable carrier matrix and methods for delivering to a patient

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 13/233100   Filing Date: 15/Sep/2011

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenetic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2010-977310 Applic. Date: 2010-12-23; US2009-634323 Applic. Date: 2009-12-09; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL B [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Publication No.: WO8202912B2  Published: 19/Jun/2012

Title: PHARMACEUTICAL COMPOSITIONS PROVIDING ENHANCED DRUG CONCENTRATIONS

Applicant/Assignee: BEND RESEARCH, INC

Application No.: 13/208305   Filing Date: 11/Aug/2011

Abstract:

A drug in a solubility-improved form is combined with a concentration-enhancing polymer in a sufficient amount so that the combination provides substantially enhanced drug concentration in a use environment relative to a control comprising the same amount of the same solubility-improved form of drug without the concentration-enhancing polymer.

Priority: US2000-742785 Applic. Date: 2000-12-20; US1999-171841P Applic. Date: 1999-12-23

Inventor: CURATOLO WILLIAM J [US]; SHANKER RAVI M [US]; BABCOCK WALTER C [US]; FRIESEN DWAYNE T [US]; NIGHTINGALE JAMES A S [US]; LORENZ DOUGLAS A [US]


Publication No.: WO8211048B2  Published: 03/Jul/2012

Title: SYSTEM AND METHOD FOR DELIVERY OF REGIONAL CITRATE ANTICOAGULATION TO EXTRACORPOREAL BLOOD CIRCUITS

Applicant/Assignee: HENRY FORD HEALTH SYSTEM

Application No.: 12/280450   Filing Date: 22/Feb/2007

Abstract:

The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable soultes.

Priority: US2006-775729P Applic. Date: 2006-02-22; WO2007US62589 Applic. Date: 2007-02-22; US2006-845646P Applic. Date: 2006-09-19; US2006-790882P Applic. Date: 2006-04-11; US2006-791055P Applic. Date: 2006-04-11; US2006-775728P Applic. Date: 2006-02-22

Inventor: SZAMOSFALVI BALAZS [US]; FRINAK STANLEY [US]; YEE JERRY [US]


Publication No.: WO8212003B2  Published: 03/Jul/2012

Title: Bifunctional fusion protein with thrombolytic and anticoagulant activities and uses thereof

Applicant/Assignee: INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA

Application No.: 10/526682   Filing Date: 10/Nov/2005

Abstract:

This application relates to a fusion protein, which is composed of a thrombolytic protein, an anticoagulant protein, and a linker peptide. In particular, the fusion protein is composed of an anticoagulant protein and a protein molecule having plasminogen-activating activity, wherein said two proteins are linked together via a linker peptide, which can be recognized and cleaved by blood coagulation factors. The application also relates to the medical use of said fusion protein, and to the use of the linker peptide which can be recognized by blood coagulation factor in linking a thrombolytic protein and an anticoagulation protein.

Priority: WO2003CN00743 Applic. Date: 2003-09-03; CN20021029086 Applic. Date: 2002-09-03

Inventor: SHI BINGXING [CN]; WU ZUZE [CN]; YU AIPING [CN]; DONG CHUNNA [CN]


Publication No.: WO8226708B1  Published: 24/Jul/2012

Title: Inflatable intraluminal graft

Applicant/Assignee: TRIVASCULAR, INC

Application No.: 10/168053   Filing Date: 03/Mar/2000

Abstract:

A collapsible stent graft for aortic aneurysms includes a collapsible inner tubular member (26) and an outer layer (24) fused or adhered thereto such as to provide a spiral inflatable member (22) therebetween. The stent graft is inserted into an artery in the collapsed state and then expanded into position by introducing a liquid into the inflatable member and sealing the member. The graft is held in place by an expandable stent (40).

Priority: GB19990004722 Applic. Date: 1999-03-03; WO2000GB00732 Applic. Date: 2000-03-03

Inventor: MURCH CLIFFORD ROWAN [GB]


Publication No.: WO8232044B2  Published: 31/Jul/2012

Title: Method of extending the shelf life of platelets using a composition comprising a short-to-ultrashort antiplatelet agent and anticoagulant and an oxygen carrier

Applicant/Assignee: BIOVEC TRANSFUSION, LLC

Application No.: 13/099061   Filing Date: 02/May/2011

Abstract:

The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Priority: US2006-330132 Applic. Date: 2006-01-12; US2005-643107P Applic. Date: 2005-01-12

Inventor: SEHGAL LAKSHMAN R [US]


Publication No.: WO8232067B2  Published: 31/Jul/2012

Title: Disrupting FCRN-Albumin Interactions

Applicant/Assignee: THE BRIGHAM & WOMEN'S HOSPITAL, INC, BRIGHAM & WOMEN'S HOSPITAL, INC

Application No.: 13/322983   Filing Date: 28/May/2010

Abstract:

Provided herein are, inter alia, methods for identifying a candidate compound for treating the toxic effects of compounds or molecules that bind to albumin in a subject. The methods include identifying test compounds that inhibit the binding between FcRn and albumin.

Priority: US2009-182479P Applic. Date: 2009-05-29; WO2010US36572 Applic. Date: 2010-05-28

Inventor: BLUMBERG RICHARD S [US]; KUO TIMOTHY T C [US]


Publication No.: WO8232105B1  Published: 31/Jul/2012

Title: Reagents and methods and systems using them

Applicant/Assignee: MAGELLAN BIOSCIENCES POINT-OF-CARE, INC

Application No.: 12/894928   Filing Date: 30/Sep/2010

Abstract:

Certain embodiments described herein are directed to a reagent that includes an effective amount of an adsorber to remove interfering species present during heavy metal level measurement in a fluid sample. In some examples, the reagent can include an effective amount of an adsorber to remove a suitable amount of glutathione from the fluid sample such that the glutathione does not interfere with measurements of lead levels in the fluid sample.

Priority:

Inventor: SCOTT W JAMES [US]


Publication No.: WO8236328B2  Published: 07/Aug/2012

Title: Pharmaceutical compositions of dispersions of amorphous drugs mixed with polymers

Applicant/Assignee: PFIZER INC, BEND RESEARCH, INC

Application No.: 12/217700   Filing Date: 08/Jul/2008

Abstract:

A pharmaceutical composition comprises a dispersion comprising a low-solubility drug and a matrix combined with a concentration-enhancing polymer. At least a major portion of the drug is amorphous in the dispersion. The compositions improve the stability of the drug in the dispersion, and/or the concentration of drug in a use environment.

Priority: US2001-300261P Applic. Date: 2001-06-22; US2002-175640 Applic. Date: 2002-06-19

Inventor: BABCOCK WALTER C [US]; CURATOLO WILLIAM J [US]; FRIESEN DWAYNE T [US]; KETNER RODNEY J [US]; LO JULIAN B [US]; NIGHTINGALE JAMES A S [US]; SHANKER RAVI M [US]; WEST JAMES B [US]


Publication No.: WO8236352B2  Published: 07/Aug/2012

Title: Glipizide compositions

Applicant/Assignee: ELAN PHARMA INTERNATIONAL LIMITED, ALKERMES PHARMA IRELAND LIMITED

Application No.: 10/701064   Filing Date: 05/Nov/2003

Abstract:

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

Priority: US2003-276400 Applic. Date: 2003-01-15; US1998-164351 Applic. Date: 1998-10-01; WO2001US15983 Applic. Date: 2001-05-18; US1999-337675 Applic. Date: 1999-06-22

Inventor: BOSCH H WILLIAM [US]; RYDE NIELS P [US]; JAIN RAJEEV A [US]; SWANSON JON [US]; HONTZ ROBERT [US]; DEVANE JOHN G [IE]; CUMMING KENNETH IAN [GB]; CLANCY MAURICE JOSEPH ANTHONY [IE]; CODD JANET ELIZABETH [IE]; LIVERSIDGE GARY G [US]


Publication No.: WO8249705B1  Published: 21/Aug/2012

Title: Devices, systems, and methods for improving left ventricular structure and function using baroreflex activation therapy

Applicant/Assignee: CVRX, INC

Application No.: 12/043754   Filing Date: 06/Mar/2008

Abstract:

Described here are devices, systems, and methods for improving left ventricular function in a patient with systolic heart failure with left ventricular dysfunction using baroreflex activation therapy. In general the systems have at least one electrode and a control system in communication with the electrode, the control system including a processor and memory, wherein the memory includes software defining a stimulus regime configured to effect improvement in left ventricular function. The methods for improving left ventricular function in a subject typically include identifying a patient in need of left ventricular function improvement and stimulating a baroreceptor with a baroreceptor activation device to improve left ventricular function.

Priority: US2007-895913P Applic. Date: 2007-03-20

Inventor: KIEVAL ROBERT S [US]; ROSSING MARTIN [US]


Publication No.: WO8252044B1  Published: 28/Aug/2012

Title: Device for in vivo delivery of bioactive agents and method of manufacture thereof

Applicant/Assignee: ADVANCED BIO PROSTHESTIC SURFACES, LTD

Application No.: 09/716146   Filing Date: 17/Nov/2000

Abstract:

The disclosure of the invention provides an implantable structural element for in vivo delivery of bioactive agents to a situs in a body. The implantable structural element may be configured as an implantable prosthesis, such as an endoluminal stent, cardiac valve, osteal implant or the like, which serves a dual function of being prosthetic and a carrier for a bioactive agent. Alternatively, the implantable structural element may simply be an implantable article that serves the single function of acting as a time-release carrier for the bioactive agent.

Priority:

Inventor: BOYLE CHRISTOPHER T [US]


Publication No.: WO8252905B2  Published: 28/Aug/2012

Title: Anti-Cd14 Antibody Fusion Protein

Applicant/Assignee: MOCHIDA PHARMACEUTICAL CO., LTD

Application No.: 11/791888   Filing Date: 05/Jun/2006

Abstract:

A protein comprising (I) an anti-CD14 antibody or its active fragment, or a derivative thereof and (II) an inhibitor for a protease, or its active fragment, or a derivative thereof is provided.

Priority: JP20050164901 Applic. Date: 2005-06-03; WO2006JP311255 Applic. Date: 2006-06-05

Inventor: FURUSAKO SHOJI [JP]; NAKAYAMA KAZUYUKI [JP]; HOSAKA YOSHITAKA [JP]; KAWAHARA TETSUSHI [JP]; NAKAMURA MASAKI [JP]; TAKEUCHI TAKASHI [JP]


Publication No.: WO8252913B2  Published: 28/Aug/2012

Title: Aptamers to Tissue Factor Pathway Inhibitor and Their Use as Bleeding Disorder Therapeutics

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 12/858369   Filing Date: 17/Aug/2010

Abstract:

The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Priority: US2010-353374P Applic. Date: 2010-06-10; US2010-367766P Applic. Date: 2010-07-26; US2010-366362P Applic. Date: 2010-07-21; US2009-234939P Applic. Date: 2009-08-18

Inventor: SCHAUB ROBERT G [US]; MCGINNESS KATHLEEN [US]; NELSON JENNIFER [US]; GENGA RYAN [US]; WATERS EMILY [US]; KURZ JEFFREY C [US]; DIENER JOHN L [US]


Publication No.: WO8256308B2  Published: 04/Sep/2012

Title: Method and device for providing blood constituents

Applicant/Assignee: ROCHE DIAGNOSTICS OPERATIONS, INC

Application No.: 13/206830   Filing Date: 10/Aug/2011

Abstract:

A metering capillary and method for providing at least one defined volume of a target constituent of a sample is provided, the method comprising providing at least one metering capillary having at least two openings

at least partly filling the metering capillary with the sample

carrying out a constituent separation for the at least partial separation of at least two constituents of the sample inside the metering capillary

and dividing the metering capillary into at least two partial pieces, wherein at least one of the partial pieces contains the defined volume of the target constituent.

Priority: EP20090152982 Applic. Date: 2009-02-17; WO2010EP00908 Applic. Date: 2010-02-15

Inventor: BUECHNER KARL-HEINZ [DE]


Publication No.: WO8257701B2  Published: 04/Sep/2012

Title: Methods for anti-fibrinolytic treatment using MMP-10 neutralizing antibody

Applicant/Assignee: PROYECTO DE BIOMEDICINA CIMA, S.L

Application No.: 12/452280   Filing Date: 26/Jun/2008

Abstract:

The present invention concerns the use of a neutralizing antibody for matrix metalloproteinase-10 (MMP-10) in the preparation of a medicine useful for anti-fibrinolytic treatment, and for hemorrhages and hemorrhagic complications of various etiologies.

Priority: ES20070001786 Applic. Date: 2007-06-26; WO2008ES00453 Applic. Date: 2008-06-26

Inventor: ORBE LOPATEGUI JOSUNE [ES]; RODRIGUEZ GARCIA JOSE ANTONIO [ES]; PARAMO FERNANDEZ JOSE ANTONIO [ES]; SERRANO VARGAS ROSARIO [ES]


Publication No.: WO8257724B2  Published: 04/Sep/2012

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/386469   Filing Date: 22/Mar/2006

Abstract:

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2003-453555P Applic. Date: 2003-03-10; US2002-235572 Applic. Date: 2002-09-06; US2005-732577P Applic. Date: 2005-10-17; US2005-726878P Applic. Date: 2005-10-14; US2004-796243 Applic. Date: 2004-03-09; US2004-769243 Applic. Date: 2004-01-30; US1998-159945 Applic. Date: 1998-09-24; US1999-433001 Applic. Date: 1999-11-02; US2001-950307 Applic. Date: 2001-09-10; US2005-727196P Applic. Date: 2005-10-14; US2004-977288 Applic. Date: 2004-10-29; US2005-727080P Applic. Date: 2005-10-14; US2005-664328P Applic. Date: 2005-03-23

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Publication No.: WO8257725B2  Published: 04/Sep/2012

Title: Delivery of highly lipophilic agents via medical devices

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/386498   Filing Date: 22/Mar/2006

Abstract:

An apparatus and system for delivering a lipophilic agent associated with a medical device including: a medical device, a first lipophilic agent capable of penetrating a body lumen, wherein the transfer coefficients of the first lipophilic agent is by an amount that is statistically significant of at least approximately 5,000, wherein the first lipophilic agent is associated with the medical device, wherein the first lipophilic agent/medical device is placed adjacent to said body lumen, and wherein a therapeutically effective amount of the first lipophilic agent is delivered to a desired area within a subject. Furthermore, the invention relates to a method for improving patency in a subject involving placement of a medical device in a body lumen for treating and/or preventing adjacent diseases or maintaining patency of the body lumen.

Priority: US2005-727080P Applic. Date: 2005-10-14; US1998-159945 Applic. Date: 1998-09-24; US2005-726878P Applic. Date: 2005-10-14; US1997-060015P Applic. Date: 1997-09-25; US2005-664328P Applic. Date: 2005-03-23; US2005-732577P Applic. Date: 2005-10-17; US2004-977288 Applic. Date: 2004-10-29; US2002-235572 Applic. Date: 2002-09-06; US2005-727196P Applic. Date: 2005-10-14; US2004-769243 Applic. Date: 2004-01-30; US2001-950307 Applic. Date: 2001-09-10; US1999-433001 Applic. Date: 1999-11-02; US2003-453555P Applic. Date: 2003-03-10

Inventor: CROMACK KEITH R [US]; TONER JOHN L [US]; BURKE SANDRA E [US]; KRASULA RICHARD W [US]; SCHWARTZ LEWIS B [US]


Publication No.: WO8257922B2  Published: 04/Sep/2012

Title: Method of profiling gene expression in a subject having alzheimer's disease

Applicant/Assignee: GENENEWS CORPORATION

Application No.: 12/757925   Filing Date: 09/Apr/2010

Abstract:

The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen.

Priority: US2009-587385 Applic. Date: 2009-10-05; US2002-268730 Applic. Date: 2002-10-09; US2000-477148 Applic. Date: 2000-01-04; US1999-115125P Applic. Date: 1999-01-06

Inventor: LIEW CHOONG-CHIN [CA]


Publication No.: WO8258117B2  Published: 04/Sep/2012

Title: COMPOSITION AND METHOD FOR THE REPAIR AND REGENERATION OF CARTILAGE AND OTHER TISSUES

Applicant/Assignee: PIRAMAL HEALTHCARE (CANADA) LTD

Application No.: 12/901293   Filing Date: 08/Oct/2010

Abstract:

The present invention relates to a new method for repairing human or animal tissues such as cartilage, meniscus, ligament, tendon, bone, skin, cornea, periodontal tissues, abscesses, resected tumors, and ulcers. The method comprises the step of introducing into the tissue a temperature-dependent polymer gel composition such that the composition adhere to the tissue and promote support for cell proliferation for repairing the tissue. Other than a polymer, the composition preferably comprises a blood component such as whole blood, processed blood, venous blood, arterial blood, blood from bone, blood from bone-marrow, bone marrow, umbilical cord blood, placenta blood, erythrocytes, leukocytes, monocytes, platelets, fibrinogen, thrombin and platelet rich plasma. The present invention also relates to a new composition to be used with the method of the present invention.

Priority: US2006-584870 Applic. Date: 2006-10-23; US2005-031325 Applic. Date: 2005-01-07; US2001-896912 Applic. Date: 2001-06-29; US2000-214717P Applic. Date: 2000-06-29

Inventor: HOEMANN CAROLINE D [CA]; BUSCHMANN MICHAEL D [CA]; MCKEE MARC D [CA]


Publication No.: WO8263125B2  Published: 11/Sep/2012

Title: Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients

Applicant/Assignee: TORRENT PHARMACEUTICALS LIMITED

Application No.: 11/134633   Filing Date: 19/May/2005

Abstract:

A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg

a process for preparing the dosage form.

Priority: IN2002MU00699 Applic. Date: 2002-08-05; IN2003MU00082 Applic. Date: 2003-01-22; US2003-630446 Applic. Date: 2003-07-29; IN2002MU00697 Applic. Date: 2002-08-05; IN2003MU00080 Applic. Date: 2003-01-22

Inventor: VAYA NAVIN [IN]; KARAN RAJESH SINGH [IN]; NADKARNI SUNIL SADANAND [IN]; GUPTA VINOD KUMAR [IN]


Publication No.: WO8263624B2  Published: 11/Sep/2012

Title: ARYL-SUBSTITUTED HETEROCYCLES, AND USE THEREOF

Applicant/Assignee: BAYER HEALTHCARE AG, BAYER INTELLECTUAL PROPERTY GMBH

Application No.: 12/302503   Filing Date: 25/May/2007

Abstract:

The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.

Priority: DE200610025314 Applic. Date: 2006-05-31; WO2007EP04693 Applic. Date: 2007-05-25

Inventor: HAERTER MICHAEL [DE]; WUNBERG TOBIAS [AT]; ALLERHEILIGEN SWEN [DE]; BAUSER MARCUS [DE]; RESTER ULRICH [DE]; HEITMEIER STEFAN [DE]


Publication No.: WO8265904B2  Published: 11/Sep/2012

Title: Automated methods for detecting sample collection with erroneous anticoagulant in clinical assays

Applicant/Assignee: ABBOTT POINT OF CARE INC

Application No.: 12/339886   Filing Date: 19/Dec/2008

Abstract:

An automatic method for identifying biological samples that are collected using the wrong blood preservative for subsequent analytical testing. The method also provides for identification and/or suppression of certain analytical test results that are substantially or partly adversely affected. The invention is particularly suited for use in point-of-care medical diagnostic testing.

Priority: US2007-015582P Applic. Date: 2007-12-20

Inventor: BROUWER ERIC [CA]; TIRINATO JODY ANN [US]; ZELIN MICHAEL P [US]


Publication No.: WO8268352B2  Published: 18/Sep/2012

Title: Modified release composition for highly soluble drugs

Applicant/Assignee: TORRENT PHARMACEUTICALS LIMITED

Application No.: 11/134632   Filing Date: 19/May/2005

Abstract:

A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise additionally another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

Priority: IN2002MU00696 Applic. Date: 2002-08-05; IN2002MU00698 Applic. Date: 2002-08-05; US2003-630348 Applic. Date: 2003-07-29; IN2003MU00081 Applic. Date: 2003-01-22

Inventor: VAYA NAVIN [IN]; KARAN RAJESH SINGH [IN]; NADKARNI SUNIL SADANAND [IN]; GUPTA VINOD KUMAR [IN]


Publication No.: WO8268361B2  Published: 18/Sep/2012

Title: Acellular bioabsorbable tissue regeneration matrices

Applicant/Assignee:

Application No.: 11/588840   Filing Date: 26/Oct/2006

Abstract:

The present invention provides methods and compositions useful in the regeneration of damaged, lost and/or degenerated tissue in humans and animals. In certain embodiments, the present invention provides an acellular bioabsorbable tissue regeneration matrix, methods of making such a matrix, and methods of using such a matrix for the regeneration of damaged, lost and/or degenerated tissue. In certain embodiments, methods and compositions of the present invention are useful in the treatment of damaged, lost and/or degenerated nerve tissue.

Priority: US2005-730614P Applic. Date: 2005-10-26

Inventor: AHLFORS JAN-ERIC W [AG]


Publication No.: WO8273566B2  Published: 25/Sep/2012

Title: METHODS AND APPARATUSES FOR CONDUCTING ASSAYS

Applicant/Assignee: MESO SCALE TECHNOLOGIES, LLC

Application No.: 12/831139   Filing Date: 06/Jul/2010

Abstract:

Disclosed are methods for conducting assays of samples, such as whole blood, that may contain cells or other particulate matter. Also disclosed are systems, devices, equipment, kits and reagents for use in such methods. One advantage of certain disclosed methods and systems is the ability to rapidly measure the concentration of an analyte of interest in blood plasma from a whole blood sample without blood separation and hematocrit correction.

Priority: US2005-145528 Applic. Date: 2005-06-03; US2004-576710P Applic. Date: 2004-06-03

Inventor: BILLADEAU MARK A [US]; DEBAD JEFF D [US]; GLEZER ELI N [US]; LELAND JONATHAN K [US]; WIJAYAWARDHANA CHARLES A [DE]


Publication No.: WO8278308B2  Published: 02/Oct/2012

Title: Diketopiperazine Salts for Drug Delivery and Related Methods

Applicant/Assignee: MANNKIND CORPORATION

Application No.: 12/886226   Filing Date: 20/Sep/2010

Abstract:

Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.

Priority: US2005-210710 Applic. Date: 2005-08-23; US2004-603761P Applic. Date: 2004-08-23

Inventor: LEONE-BAY ANDREA [US]; MOYE-SHERMAN DESTARDI [US]; WILSON BRYAN R [US]


Publication No.: WO8287739B2  Published: 16/Oct/2012

Title: MEASURING HEMATOCRIT AND ESTIMATING HEMOGLOBIN VALUES WITH A NON-INVASIVE, OPTICAL BLOOD MONITORING SYSTEM

Applicant/Assignee: FRESENIUS MEDICAL CARE HOLDINGS, INC

Application No.: 13/366119   Filing Date: 03/Feb/2012

Abstract:

An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting.

The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Priority: US2008-265392 Applic. Date: 2008-11-05

Inventor: BARRETT LOUIS LEEGRANDE [US]; PETERSON DAVID WAYNE [US]; SAMMANN KRISTIAN ALLEN [US]


Publication No.: WO8288116B2  Published: 16/Oct/2012

Title: Methods and Compositions for Isolating Metastatic Cancer Cells, and Use in Measuring Metastatic Potential of a Cancer Thereof

Applicant/Assignee: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK

Application No.: 12/725036   Filing Date: 16/Mar/2010

Abstract:

The present invention relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. The invention further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the identification of agents having anti-metastatic potential. The present invention further provides methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipetidyl peptidase IV (DPPIV)] expressed on the surface of metastasizing cancer cells.

Priority: US2000-231517P Applic. Date: 2000-09-09; WO2001US26735 Applic. Date: 2001-08-28; US2002-220347 Applic. Date: 2002-08-28

Inventor: CHEN WEN-TIEN [US]


Publication No.: WO8288423B2  Published: 16/Oct/2012

Title: FXA INHIBITORS WITH CYCLIC AMIDINES AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Applicant/Assignee: LEGOCHEM BIOSCIENCE LTD

Application No.: 12/598010   Filing Date: 09/May/2008

Abstract:

The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.

Priority: KR20070044980 Applic. Date: 2007-05-09; KR20080042740 Applic. Date: 2008-05-08; WO2008KR02619 Applic. Date: 2008-05-09

Inventor: CHO YOUNG LAG [KR]; SONG HO YOUNG [KR]; LEE DAE YON [KR]; BAEK SUNG YOON [KR]; CHAE SANG EUN [KR]; JO SANG HUI [KR]; KIM YEON OK [KR]; LEE HYANG SOOK [KR]; PARK JU HYUN [KR]; PARK TAE KYO [KR]; WOO SUNG HO [KR]; KIM YONG ZU [KR]


Publication No.: WO8292068B2  Published: 23/Oct/2012

Title: MEDICAL DEVICE PACKAGE

Applicant/Assignee: TYCO HEALTHCARE GROUP LP

Application No.: 13/292129   Filing Date: 09/Nov/2011

Abstract:

The present disclosure provides a package for a medical device containing a cavity for receiving the medical device, a first closure having a sealed portal therein and a second closure adjacent the first closure.

Priority: US2009-528561 Applic. Date: 2009-08-25; WO2008US02458 Applic. Date: 2008-02-26; US2007-904927P Applic. Date: 2007-03-05

Inventor: STOPEK JOSHUA B [US]; KIRSCH DAVID [US]


Publication No.: WO8292799B2  Published: 23/Oct/2012

Title: Biological artificial blood vessel and method of making

Applicant/Assignee: GRANDHOPE BIOTECH CO., LTD

Application No.: 11/494817   Filing Date: 28/Jul/2006

Abstract:

A prosthetic device for implantation into a human body is made by a method that includes the steps of providing a natural animal tissue that has a substrate, crosslinking and fixing the substrate, minimizing the antigens from the substrate, tanning the substrate to improve its mechanical properties, and coupling an anticoagulant to an inner surface of the substrate to form an anticoagulant surface layer.

Priority: CN20051036175 Applic. Date: 2005-07-29

Inventor: XU GUO-FENG [CN]


Publication No.: WO8293232B2  Published: 23/Oct/2012

Title: Flowable carrier matrix and methods for delivering to a patient

Applicant/Assignee: WARSAW ORTHOPEDIC, INC

Application No.: 13/353632   Filing Date: 19/Jan/2012

Abstract:

A carrier matrix may be delivered to a target position within a patient in a minimally invasive manner by first cutting a collagen sponge sheet into a plurality of relatively small pieces. These pieces are sized so that, when wet, they are capable of flowing through a cannula and/or reduced-diameter syringe tip. The pieces are placed into a syringe and wetted, say with a morphogenetic solution, and optionally mixed with a bulking material, which is similarly sized to fit through the cannula. The thoroughly mixed and wetted product forms a viscous aggregate which may then be injected into the patient at the target site.

Priority: US2009-635289 Applic. Date: 2009-12-10; US2006-504363 Applic. Date: 2006-08-14

Inventor: BEALS NEIL B [US]; SCIFERT JEFFREY L [US]; BODEN SCOTT D [US]


Publication No.: WO8293277B2  Published: 23/Oct/2012

Title: CONTROLLED-RELEASE NANOPARTICULATE COMPOSITIONS

Applicant/Assignee: ALKERMES PHARMA IRELAND LIMITED

Application No.: 09/337675   Filing Date: 22/Jun/1999

Abstract:

Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Priority: US1998-164351 Applic. Date: 1998-10-01

Inventor: SWANSON JON [US]; JAIN RAJEEV A [US]; HONTZ ROBERT [US]; DEVANE JOHN G [IE]; CUMMING KENNETH IAIN [GB]; CLANCY MAURICE JOSEPH ANTHONY [IE]; CODD JANET ELIZABETH [IE]; LIVERSIDGE GARY [US]


Publication No.: WO8303518B2  Published: 06/Nov/2012

Title: Autonomous, ambulatory analyte monitor or drug delivery device

Applicant/Assignee: ROSEDALE MEDICAL, INTUITY MEDICAL, INC

Application No.: 11/311667   Filing Date: 20/Dec/2005

Abstract:

The invention relates to analyte monitoring/drug (pharmaceutical agent) delivery device. The invention is suited for monitoring various blood constituents such as glucose. The device has a housing that at least partially encloses a plurality of microneedles disposed on a carrier and an electronics portion. Each microneedle is in fluid communication with a corresponding microchannel. Each microneedle is individually addressable. That is, each microneedle can be extended and retracted individually via an actuator. The electronics portion includes a processor and associated circuitry (e.g., memory, supporting electronics and the like), a motor or the like, a sensor, a power supply (e.g., battery) and optionally an interface. In general, the processor controls the operation of the device and is data communication with the actuator, motor, sensor and interface.

The invention provides for autonomous operation, that is, without intervention of the user. The invention can optionally provide for calibration without intervention of the user. The invention can also provide for semi-continuous monitoring for day and night time. The invention can provide for up to four, or more, weeks of operation. The invention can provide for a device that is relative small in size, and therefore unobtrusive. The invention can also provide for device with remote control and interactive electronics. The invention may be also used for the delivery of various pharmaceutical agents including high potency drugs to minimize patient intervention and minimize discomfort.

Priority: US2002-131268 Applic. Date: 2002-04-23; US2002-355195P Applic. Date: 2002-02-08

Inventor: ACETI JOHN GREGORY [US]; MCBRIDE STERLING EDUARD [US]; MORONEY RICHARD MORGAN [US]; GREGORY CHRISTOPHER CARTER [US]; ZANZUCCHI PETER JOHN [US]


Publication No.: WO8303642B1  Published: 06/Nov/2012

Title: Metal injection molded tubing for drug eluting stents

Applicant/Assignee: ADVANCED CARDIOVASCULAR SYSTEMS, INC

Application No.: 10/444277   Filing Date: 23/May/2003

Abstract:

An intravascular stent is formed by utilizing the process of metal injection molding (MIM) applied to metal powder, ceramic powder and ceramic metal composite powder. The devices may have longitudinal/circumferential channels and/or depots molded into the tubing thereof to enable such devices to act as a functional drug delivery vehicle having adequate drug reservoir capability.

Priority:

Inventor: CARLSON JAMES M [US]


Publication No.: WO8304205B2  Published: 06/Nov/2012

Title: Blood Coagulation Assays

Applicant/Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH

Application No.: 12/569714   Filing Date: 29/Sep/2009

Abstract:

The invention relates to methods for determining the activity of a proteolytic coagulation factor of the blood coagulation cascade in a body fluid such as whole blood or plasma. A combination is provided in a reaction mixture. The combination comprises the sample and an activation agent for activating a proteolytic coagulation factor of the blood coagulation cascade or for activating the blood coagulation cascade. The effect of the activating on a reagent system comprising a cleavable moiety is evaluated. The cleavable moiety is or becomes bound to a chemiluminescent agent or a sensitizer agent or both. The chemiluminescent agent and the sensitizer agent are related in that, when in close proximity, energization of the sensitizer agent results in energization of the chemiluminescent agent.

The effect of the activating is related to the activity of a proteolytic coagulation factor of the blood coagulation cascade wherein the effect is the extent of cleavage of the cleavable moiety.

Priority: EP20080017334 Applic. Date: 2008-10-02

Inventor: KAPPEL ANDREAS [DE]; LICHTE ANDREA [DE]; ZANDER NORBERT [DE]; TEIGELKAMP STEFAN [DE]; SCHELP CARSTEN [DE]


Publication No.: WO8317750B2  Published: 27/Nov/2012

Title: FLOW BALANCING AND SYNCHRONIZATION SYSTEM AND METHOD, ESPECIALLY FOR CITRATE

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A

Application No.: 12/763864   Filing Date: 20/Apr/2010

Abstract:

A renal failure therapy system includes a blood pump

a citrate pump

and a control unit configured to automatically control the blood pump and the citrate pump to achieve a citrate flowrate that is based on a blood flowrate, so that the flowrates are synchronized.

Priority: US2006-356661 Applic. Date: 2006-02-16; US2003-685724 Applic. Date: 2003-10-15

Inventor: WARE LEE C [US]; BOEHNLEIN ARNOLD F [US]


Publication No.: WO8317799B2  Published: 27/Nov/2012

Title: THERAPEUTIC MATERIAL DELIVERY SYSTEM FOR TISSUE VOIDS AND CANNULATED IMPLANTS

Applicant/Assignee: BIOACTIVE SURGICAL, INC

Application No.: 12/414194   Filing Date: 30/Mar/2009

Abstract:

Described herein is a novel drug delivery assembly having particular applicability to the field of orthopedic and surgical medicine. The devices and assemblies described herein enable the efficient application and retention of potentially expensive therapeutic materials to very specific locations, particularly those associated with voids in bone and tissue. One particularly unique aspect of the present invention involves the introduction of constructs which promote the retention of therapeutic material in the target area of application for beneficial use, for example by forming a proximal barrier that prevents leakage of the therapeutic material out of the target area. Additionally, the present invention provides unique devices and methods for surgical introduction of such constructs.

The present invention finds particular application in connection with introduction of stem and progenitor cells, bioactive molecules and bone scaffold materials in conjunction with bone voids and with the use of cannulated implants, such as bone screws (also surgical screws) and pins. The present invention also has beneficial use in the delivery of cancer drugs, antimicrobials, bone cements and other therapeutic materials.

Priority: US2008-116465P Applic. Date: 2008-11-20; US2009-154718P Applic. Date: 2009-02-23

Inventor: SCHON LEW C [US]; SPEDDEN RICHARD H [US]; PINGEL LAURA J [US]


Publication No.: WO8318153B2  Published: 27/Nov/2012

Title: Method of medically treating an individual

Applicant/Assignee:

Application No.: 11/478070   Filing Date: 29/Jun/2006

Abstract:

A method immunizing an individual that minimizes the amount of antigen or attenuated organism needed and the number of doses and clinic visits required, while making possible polyvalent simultaneous immunizations. The method comprises the steps of obtaining a sample of blood. Exposing at least a portion of this sample to at least one immunogenic antigen, attenuant or other immunogen. Incubating the exposed sample under specified optimal conditions and introducing this exposed sample into the individual to effect immunization thereof. The method of the invention also provides a method of delivery of materials, other than antigens, throughout an individual's body such as therapeutic drugs, virus vectors, genes, DNA, RNA, isotopes, and other therapeutic substances. A method for the delivery of treatment material to an individual is also provided by this method.

Priority:

Inventor: NALIN DAVID R [US]


Publication No.: WO8323615B2  Published: 04/Dec/2012

Title: Methods of processing multi-phasic dispersions

Applicant/Assignee: BAXTER INTERNATIONAL INC, BAXTER HEALTHCARE S.A, BAXTER HEALTHCARE S. A

Application No.: 12/195149   Filing Date: 20/Aug/2008

Abstract:

A method for processing multi-phasic dispersions is provided. The method comprises providing a multi-phasic dispersion, the dispersion including dispersed and continuous phases, the dispersion comprising solid microparticles, providing a non-solvent, combining the multi-phasic dispersion and the non-solvent, and selectively effecting migration of the dispersed phase into or through the non-solvent such that the microparticles are separated from the dispersion.

Priority:

Inventor: PIRAN URI [US]


Publication No.: WO8328720B2  Published: 11/Dec/2012

Title: MEMS INTERSTITIAL PROTHROMBIN TIME TEST

Applicant/Assignee: INFOTONICS TECHNOLOGY CENTER, INC

Application No.: 12/189509   Filing Date: 11/Aug/2008

Abstract:

A method of determining a prothrombin time is disclosed. A mediator is applied to a stratum corneum. The stratum corneum is penetrated to allow the mediator to enter a region containing interstitial fluid and interact with at least one capillary, causing blood and/or blood components to leak from the at least one capillary into the region containing interstitial fluid. A characteristic affected by the blood and/or blood components is measured in the region containing interstitial fluid which correlates to the prothrombin time. A system for measuring prothrombin time is also disclosed.

The system has a mediator, one or more microneedles, and a processor directly or indirectly coupled to the one or more microneedles and configured to determine a coagulation change in blood or blood components in a region around the one or more microneedles after the one or more microneedles penetrate a stratum corneum.

Priority: US2007-955054P Applic. Date: 2007-08-10

Inventor: MIR JOSE [US]; KOWARZ MAREK W [US]; SARBADHIKARI KAMAL K [US]; ASHE PHILIP RYAN [US]


Publication No.: WO8328842B2  Published: 11/Dec/2012

Title: FILTER ELEMENT WITH RETRACTABLE GUIDEWIRE TIP

Applicant/Assignee: SALVIAC LIMITED

Application No.: 13/022040   Filing Date: 07/Feb/2011

Abstract:

A medical guidewire assembly comprises a guidewire having a flexible tip. A medical device such as a collapsible filter for use as an embolic protection device is mounted on the guidewire. The filter is advanced through a body lumen with the guidewire tip extending distally. A variable thickness guidewire (having a recess or thinner segment between thicker segments) can be employed. At a first location the filter is advanced relative to the tip to a location which is distally advanced from the first location. Placement of the filter in an optimal distal location is thereby achieved.

Priority: IE19970000789 Applic. Date: 1997-11-07; IE19980000267 Applic. Date: 1998-04-08; WO1999IE00039 Applic. Date: 1999-05-07; US2008-339375 Applic. Date: 2008-12-19; US2002-189375 Applic. Date: 2002-07-03; US2001-986060 Applic. Date: 2001-11-07; WO2000IE00057 Applic. Date: 2000-05-08; US1998-188472 Applic. Date: 1998-11-09

Inventor: BRADY EAMON [IE]


Publication No.: WO8329468B2  Published: 11/Dec/2012

Title: Methods for collecting and using placenta cord blood stem cell

Applicant/Assignee: CORD BLOOD SCIENCE INC

Application No.: 12/268319   Filing Date: 10/Nov/2008

Abstract:

An innovative method of collecting cord blood stem cells from an isolated mammalian non-exsanguinated or partially exsanguinated placenta by placental perfusion is described and also an easy method for safe long duration cold storage of the placenta. Placental perfusion can include perfusing the isolated placenta with a pulsatile flow of perfusion solution, for example, using a pulsatile or peristaltic pump or device. The stem cells can then be isolated from the perfusate. Significantly increased amounts of CD133+ stem cells can be collected from the perfusate. The perfusion solution can include an anticoagulant. The isolated mammalian placenta need not be treated with an anticoagulant prior to perfusing. The isolated placenta can be free from an anticoagulant prior to perfusing.

Priority: WO2007US11359 Applic. Date: 2007-05-11; US2006-799734P Applic. Date: 2006-05-11

Inventor: TAKEBE NAOKO [US]


Publication No.: WO8329641B2  Published: 11/Dec/2012

Title: Remedies for ischemic disease of the limbs comprising administration of G-CSF

Applicant/Assignee: CHUGAI SEIYAKU KABUSHIKI KAISHA

Application No.: 10/380200   Filing Date: 13/Mar/2003

Abstract:

An effective agent for treating ischemic disease, the agent containing human granulocyte colony-stimulating factor (human G-CSF) as an active ingredient is disclosed. By administering this therapeutic agent, an effective therapy particularly for obstructive arteriosclerosis is provided which can eliminate drawbacks with conventional therapies, such as kinesitherapy, pharmacotherapy, and revascularization, and recently proposed therapies, such as gene therapy and intramuscular transplantation of bone marrow cells. Furthermore, the therapeutic agent can be used as an agent for treating ischemic disease, such as ischemic cerebrovascular disorder or ischemic heart disease.

Priority: JP20000277562 Applic. Date: 2000-09-13; WO2001JP07946 Applic. Date: 2001-09-13

Inventor: MIYAI TATSUYA [JP]; TAMURA MASAHIKO [JP]


Publication No.: WO8336917B2  Published: 25/Dec/2012

Title: Color coded anatomical and non-anatomical sticker labels to be used on medication bottles to identify what medication is used for and when medication is due to be administered

Applicant/Assignee:

Application No.: 12/662454   Filing Date: 19/Apr/2010

Abstract:

Current medication labels are very difficult for people with disabilities, language barriers, functional impairments, or illiteracy to read, potentially increasing the risk for accidental medication overdoses and/or poor compliance with medication administration and adherence. By having a color coded sticker system with an enclosed full body guide in the form of a poster, and a home health medication record card, these stickers are placed on each medication bottle as a symbol for what the medication is used for. The stickers are color coded in order to distinguish the time the medication is to be administered. Home health agencies may use the poster and stickers as they educate their patients about the medications they take.

Priority: US2009-267544P Applic. Date: 2009-12-08

Inventor: DOIRON WHITNEY [US]

...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
World Patents Published in 2013
World Patents Published in 2011
WORLD - PCT PATENT DOCUMENTS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM IN 2012
This list includes World Patent Documents published by PCT. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs,
medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin
and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve highly relevant documents.